Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GlobalFoundries Inc. Ordinary Shares vs Natera Inc. Common Stock — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $47.2 (market cap $27.28B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× GlobalFoundries Inc. Ordinary Shares's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.98% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 1 Days and Natera Inc. Common Stock for 0 Days on average.
| GFS | NTRA | |
|---|---|---|
Market Cap | $27.28B | $57.03B |
Volume | 13,755,528 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $89.96 | $425.64 |
52-Week Low | $32.24 | $179.42 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $26.57B | $56.18B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GlobalFoundries (GFS) trades at $46.70, down 3.39% on the day, with technical indicators showing a neutral to bearish short-term bias. The company maintains solid fundamentals with $6.79B revenue and 10.32% net margin, though profitability declined year-over-year. Recent catalysts include a landmark $21B Japan-backed fab expansion and strategic partnerships with TSMC and Marvell for AI-related semiconductor production, positioning GFS for long-term growth in the semiconductor sector.
While near-term technical weakness persists, GFS's strategic positioning in AI infrastructure and substantial government-backed expansion create compelling long-term opportunities. Risks include execution challenges with massive capital projects and semiconductor cycle volatility. With 57.9% analyst buy ratings and a $79.69 consensus target representing 71% upside, Wall Street remains optimistic about GFS's growth trajectory despite current market softness.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GlobalFoundries Inc. Ordinary Shares
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
